Information  X 
Enter a valid email address

Braveheart Inv Group (BRH)

  Print      Mail a friend

Friday 18 September, 2020

Braveheart Inv Group

Update on the Pharm2Farm anti-viral mask project

RNS Number : 3730Z
Braveheart Investment Group plc
18 September 2020
 

RNS Reach announcement (non-regulatory)

 

18 September 2020

Braveheart Investment Group plc

("Braveheart" or the "Group")

Update on the P harm2Farm anti-viral mask project

Braveheart Investment Group (AIM: BRH), is pleased to announce that Pharm 2 Farm Limited ("P2F") has placed an order for an automated face mask production line which is expected to be delivered in November 2020 and commissioned by the end of December 2020.

 

The face mask production line, which is manufactured in Europe, has the capacity to produce up to five million standard or anti-viral face masks per month.

 

Conventional surgical type masks typically comprise of three layers, with the inner layer acting as a physical barrier to viruses and bacteria. However, they are only recommended for up to two hours of continual use as this layer can become moist and fail, thereby allowing the virus to penetrate though. P2F has developed a second defensive layer that incorporates its own nanotechnology, which is engineered to kill viruses and bacteria. Combining this new active layer with the physical barrier layer, to produce four layer (ply) masks, is expected to improve user safety over a prolonged use. This new material is currently undergoing testing, specifically, with respect to the time taken to kill viruses, including COVID-19. These tests are, being undertaken at the University of Nottingham and results are expected by the beginning of October. Following a satisfactory outcome of the tests undertaken at the University of Nottingham, it is envisaged that manufacture of the anti-viral face masks will commence in the first quarter of 2021. In the event that these tests do not provide a satisfactory outcome, the production line will be used to produce conventional surgical type masks, which P2F believe could still be produced on a profitable basis.

 

 

 

 

For further information: 

 

 

 

 

Braveheart Investment Group plc

Tel: 01738 587555

Viv Hallam, Executive Director

 

 

 

Allenby Capital Limited (Nominated Adviser and Joint Broker)

Tel: 020 3328 5656

David Worlidge / James Hornigold

 

 

 

Peterhouse Capital Limited (Joint Broker)

Tel: 020 7469 0936

Heena Karani / Lucy Williams

 

 

About RNS Reach announcements

 

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.
 
END
 
 
NRAGPUGWBUPUPWM

a d v e r t i s e m e n t